Key terms
About CRNX
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRNX news
Apr 05
10:40am ET
Biotech Alert: Searches spiking for these stocks today
Apr 04
5:02pm ET
Crinetics Pharmaceuticals Launches New Deferred Compensation Plan
Mar 25
4:55am ET
JMP Securities biotech analysts to hold an analyst/industry conference call
Mar 22
5:12pm ET
JMP Securities biotech analysts to hold an analyst/industry conference call
Mar 22
11:33am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
2:36am ET
Buy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market Potential
Mar 21
2:15am ET
Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results
Mar 20
8:00am ET
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX)
Mar 20
7:43am ET
Crinetics price target raised to $55 from $54 at Oppenheimer
Mar 20
6:13am ET
Crinetics price target raised to $80 from $60 at JMP Securities
Mar 20
6:04am ET
Crinetics price target raised to $60 from $50 at H.C. Wainwright
Mar 20
6:02am ET
3 Best Stocks to Buy Now, 3/20/2024, According to Top Analysts
Mar 19
4:16pm ET
JonesResearch ups Crinetics target, sees more room to run for shares
Mar 19
4:08pm ET
Crinetics files to sell 8.33M shares of common stock for holders
Mar 19
12:25pm ET
Paltusotine: A Potential Game-Changer in Acromegaly Treatment, Analyst Recommends Buy
Mar 19
8:40am ET
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)
Mar 19
6:42am ET
Crinetics Pharmaceuticals’ Paltusotine Shows Promising Results
Mar 19
6:04am ET
Crinetics’ paltusotine in acromegaly meets all Phase 3 study endpoints
Mar 13
1:20pm ET
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)
Mar 13
7:27am ET
Crinetics price target raised to $54 from $48 at Oppenheimer
Mar 13
6:20am ET
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)
Mar 13
12:25am ET
Buy Rating Affirmed for Crinetics Pharmaceuticals as Paltusotine Shows Promising Phase 2 Results and Market Potential
Mar 12
4:44pm ET
Crinetics Pharmaceuticals Advances with Promising Phase 2 Results
Mar 12
4:11pm ET
Crinetics reports topline results from paltusotine study
Mar 11
7:01am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Crinetics Pharmaceuticals (CRNX)
Mar 08
6:04am ET
Crinetics price target raised to $50 from $42 at H.C. Wainwright
Mar 06
4:59am ET
Crinetics initiated with a Buy at Citi
Mar 01
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
2:05pm ET
Strong Buy Rating for Crinetics Pharmaceuticals Amidst Financial Fortitude and Promising Clinical Trials
Feb 29
8:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)
No recent press releases are available for CRNX
CRNX Financials
Key terms
Ad Feedback
CRNX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRNX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range